コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 matched controls (median follow-up 2.5 years after imaging).
2 45 days after imaging, and more than 45 days after imaging).
3 rrogating the sample once freed from the gel after imaging.
4 earance of the skin were recorded before and after imaging.
5 excised tumor sections obtained immediately after imaging.
6 multi-area electrophysiology weeks to months after imaging.
7 , multi-site electrophysiology several weeks after imaging.
8 s performed during infusion and at 1 and 7 d after imaging.
9 pressure measurements were obtained on GD18 after imaging.
10 e in serum Cr levels and GFRs from before to after imaging.
11 (59.7%) for disease detected up to 12 months after imaging.
12 cases in which the regimen was not completed after imaging.
13 er imaging, 3-5 days after imaging, 6-9 days after imaging, 10-45 days after imaging, and more than 4
14 they were obtained (before imaging, 1-2 days after imaging, 3-5 days after imaging, 6-9 days after im
15 re imaging, 1-2 days after imaging, 3-5 days after imaging, 6-9 days after imaging, 10-45 days after
17 for automatic fluorescence channel selection after image acquisition and accurate prediction of fluor
24 time point mice were immediately sacrificed after imaging and aortas were excised for mass spectrome
27 xpected management was documented before and after imaging, and data about all treatments and PSA lev
30 animals of group 2 were euthanized on day 7 after imaging, and Ki-67, TUNEL, ERalpha, and ERbeta sta
32 each group were collected randomly on day 3 after imaging, and terminal deoxyribonucleotidyl transfe
35 ical solution from the mouth, akin to colour after-images appearing on 'white' paper after fixation o
43 residual disease manifesting up to 9 months after imaging but lower (59.7%) for disease detected up
46 nificantly predicted dysphoria for 27 months after imaging controlling for prior dysphoria (beta = -.
47 GFRs increased in both groups from before to after imaging (CT group, P </= .01; MR imaging group, P
50 ed agent that combines targeted radiotherapy after imaging dosimetry with the potential for single-ag
54 siological measurements made weeks to months after imaging (e.g., in subjects undergoing behavioral t
58 2 hours before imaging and at least one time after imaging (>1 day after administration of contrast m
59 III randomized trial, compared late toxicity after image-guided intensity-modulated radiotherapy (IG-
60 imprecise, with 30-50% of patients recurring after image-guided radiotherapy or radical prostatectomy
69 s performed to identify risk factors for AKI after imaging, including the effects of eGFR and intrave
70 cies, and by measuring the properties of the after-images, including their duration, size scaling, co
71 30 patients delivered between 18 and 89 days after imaging (mean, 55 days) (late delivery group).
74 of being diagnosed as having an MDD episode after imaging (odds ratio, 0.96; 95% CI, 0.01-0.75; P =
76 ('blindsight') nevertheless reported visible after-images of the stimuli when they were turned off ('
77 ontinued to carry image-specific information after image offset, but most ceased to encode previously
78 arge deviations from baseline firing shortly after image onset but relaxing back to baseline at diffe
79 ls explained earlier vERP variability (88 ms after image onset), whereas high-level models explained
81 many neurons of morphology and connectivity after imaging or co-registration within a common templat
83 row Angle Camera (NAC) temporal ('before and after') image pairs to quantify the contemporary rate of
86 ring the earliest encoding period (0-2000 ms after image presentation) in these trials there was a wi
94 rdiac motion estimation that will be applied after image registration and demonstrate its effectivene
118 [13.7]; 53 253 [52.8%] female) were included after images underwent quality control and potentially c
119 >mean + 1 SD) developed TTS ~2 years earlier after imaging vs. those with lower AmygA (P=0.028).
122 ls recovered by bronchoalveolar lavage (BAL) after imaging were stained immunohistochemically for iNO
124 erum creatinine (SCr) measurement before and after imaging who underwent CT with intravenous ICM or a
125 ed in which a decision not to treat was made after imaging with (111)In-ibritumomab tiuxetan (4.0% of
126 not treated with (90)Y-ibritumomab tiuxetan after imaging with (111)In-ibritumomab tiuxetan, because